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Abstract: Melanoma is an immunogenic cancer. However, the ability of the immune   system 
to eradicate melanoma tumors is affected by intrinsic negative regulatory mechanisms.   Multiple 
immune-modulatory therapies are currently being developed to optimize the immune response 
to melanoma tumors. Two recent Phase III studies using the monoclonal antibody ipilimumab, 
which targets the cytotoxic T-lymphocyte antigen (CTLA-4), a negative regulator of T-cell 
activation, have demonstrated improvement in overall survival of metastatic melanoma 
patients. This review highlights the clinical trial data that supports the efficacy of ipilimumab, 
the immune-related response criteria used to evaluate clinical response, and side-effect profile 
associated with ipilimumab treatment.
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Introduction
It has long been understood that among cancer types, melanoma is potentially treatable 
using immunologically-based therapies. Infiltrating lymphocytes are often present in 
tumors, demonstrating an immune response to melanoma tumors. However, infiltrating 
T-cells fail to be sufficiently activated to result in tumor reduction. Methods to enhance 
the T-cell response to melanoma tumors have shown promise. Treatment of metastatic 
melanoma with high dose interleukin-2 (IL-2), which stimulates T-cell activity, results 
in objective response rates of approximately 15% and durable complete response rates 
in up to 6% of cases.1,2 Adoptive T-cell Transfer (ACT), in which tumor-reactive 
lymphocytes are stimulated ex vivo and expanded before being re-introduced into 
the patient, has shown objective response rates of 50%–70%.3,4 Recent data indicates 
that ACT using lymphodepleting preparative regimens can result in durable complete 
responses in up to ∼20% of patients in a highly selected population.5 Finally, a fully 
human IgG4 antibody that blocks programmed death 1 (PD-1) inhibitory receptor on 
activated T-cells has shown encouraging results in early clinical trials, with 15 of 46 
evaluable melanoma patients achieving objective responses in a Phase II study.6 All 
of these patients remained on trial at the time of presentation, suggesting potential 
durable responses are obtainable with anti-PD-1 treatment. Despite the potential of 
enhancing the native immune response to metastatic melanoma tumors, it is clear that 
there are complexities of the immune response that thwart the ability of T-cells to 
sufficiently attack melanoma tumors in most patients.
T-cell activation requires costimulatory signals. Melanoma antigens that are 
bound to the major histocompatibility complex (MHC) on antigen-presenting cells 
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(APCs) require the costimulation of CD28 receptor on T-cells 
by CD80 or CD86 ligands on APCs for T-cell activation 
 ( Figure 1). The cytotoxic T-lymphocyte antigen-4 (CTLA-4) 
can bind with greater affinity to CD80 and CD86, and thus 
disrupt the necessary costimulatory signal provided by APCs. 
This led to the hypothesis that blockade of CTLA-4 function 
may allow for optimal costimulation of CD28 receptors on 
T-cells by APC CD80/86, and enhanced T-cell activation. 
Ipilimumab (YervoyTM Bristol-Myers Squibb, New York, 
NY) is a recombinant human IgG1κ monoclonal antibody 
that binds to CTLA-4 and blocks binding to CD80 or CD86 
on APCs. Multiple elegant pre-clinical and early phase 
clinical studies demonstrated the proof of principle of this 
approach,7,8 and ipilimumab is now the first treatment in a 
randomized study to demonstrate a clear overall survival 
benefit in metastatic melanoma.9
Pharmacology
Mechanism of action
Ipilimumab belongs to a class of immunomodulatory agents 
which alters the inherent balance of the immune system. It is a 
monoclonal antibody targeting the immune protein cytotoxic 
T-lymphocyte antigen (CTLA-4). CTLA-4 is a negative 
regulator of T-cell activation and is expressed on activated 
T-cells as well as on T-regulatory cells. When T-cells bind 
to APCs, a costimulatory signal is needed to potentiate T-cell 
activation. This costimulatory signal takes the form of CD28, 
present on the T-cell, binding to the B7 family of receptors 
expressed by APC. CTLA-4 is also capable of binding to 
B7 receptors and, in doing so, inhibits costimulation and 
activation of T-cells.10,11 CTLA-4 knockout mice universally 
experience a fatal syndrome of lymphoproliferation which 
provides evidence for the key function of CTLA-4 as a 
negative regulator of the immune system.12–14 Interestingly, 
blockade of CTLA-4 does not lead to nonspecific T-cell 
activation but it does appear to augment immune responses 
in mice.11 Ipilimumab was developed with a transgenic 
murine model to create a monoclonal antibody with human 
immunoglobulin genes that binds CLTA-4, and blocks its 
interactions with B7.15,16
Physical properties
Ipilimumab is a fully human monoclonal antibody with two 
heavy chains and two kappa light chains linked together by 
way of disulfide bonds. The molecular weight is approxi-
mately 148 kDa and it exists in solution at a physiologic 
pH of 7.0.
Pharmacokinetics
Pharmacokinetic data was originally generated in mouse and 
cynomolgus monkey models.15,17 After infusion of a 10 mg/kg 
dose, the steady-state volume of distribution of ipilimumab 
was similar to the plasma volume of ipilimumab in cynomol-
gus monkeys. This implies that ipilimumab remains within 
the vasculature and does not undergo tissue distribution.18 
Ipilimumab is systemically cleared and is not affected by 
hepatic or renal organ function in patients with a creati-
nine clearance of $29 mL/minute.19   Additionally, it is not 
metabolized via cytochrome P450 pathways; it is expected 
to undergo degradation into small peptides and amino acids 
and undergo excretion via normal protein catabolism. The 
half-life of the drug is 14.7 days and steady state is estab-
lished by the third dose when administered every 3 weeks. 
  Pursuant to these studies, a Phase I trial evaluated ipilimumab 
at 0.3 mg/kg, 1 mg/kg, and 3 mg/kg.20,21
Clinical applications
Phase i trials
The first human clinical studies were initiated at doses 
















Figure 1 Ipilimumab blocks the costimulatory signal required for T-cell activation. 
Antigen-presenting cells (APCs) present melanoma antigens bound to the major 
histocompatibility  complex  (MHC)  to  T-cells.  Costimulation  of  CD28  receptor 
on T-cells by CD80 or CD86 ligands on APCs is also required for optimal T-cell 
activation. The cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T-cells can bind with 
greater affinity to CD80 and CD86, and thus disrupt the necessary costimulatory 
signal provided by APCs. Ipilimumab binds to CTLA-4 and blocks its binding to CD80 
or CD86 on APCs allowing for costimulation of CD28 receptors on T-cells by APC 
CD80/86, and optimal T-cell activation. 9,10
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solid tumors.21–23 The 3 mg/kg dose was selected for further 
  testing in humans based upon trough levels. Early studies did 
not establish a maximum tolerated dose and further clinical 
studies pushed the dose up to 10 mg/kg. Nonetheless, dose-
limiting toxicities were noted in nearly all early studies of 
ipilimumab.21,24 These studies also noted that multiple-dose 
induction regimens given every 3 weeks improved disease 
control rates over single-dose induction regimens.25 The 
most notable responses were seen repeatedly in metastatic 
melanoma.
Phase ii trials in melanoma demonstrate 
dose-dependent responsiveness
In a Phase II dose-finding study of ipilimumab in metastatic 
melanoma, responses were noted in a dose-dependent fash-
ion when ipilimumab was dosed at 0.3 mg/kg, 3 mg/kg, and 
10 mg/kg every 3 weeks for four doses and analyzed using a 
statistical trend test.26 Ipilimumab was noted to be clinically 
active at doses of 3 mg/kg and higher. In a Phase II study of 
ipilimumab at 3 mg/kg every 4 weeks for four doses alone or 
in combination with dacarbazine 250 mg/m2/day for 5 days for 
up to six courses, there was no statistically significant differ-
ence in response rate between the two arms (5.4% vs 14.3%, 
respectively).27 Without a significant increase in toxicity, 
further studies of ipilimumab at 10 mg/kg showed best over-
all response rates by WHO modified criteria in the range of   
5.8%–15.8%.28,29 An ongoing Phase II single-institution trial 
(NCT01119508) seeks to further evaluate ipilimumab 10 mg/kg 
in combination with temozolomide. The primary endpoint of 
this study is the rate of 6-month progression-free survival with 
a secondary endpoint of overall response rate. These Phase II 
studies also evaluated the use of ipilimumab in a maintenance 
setting after four doses of induction   ipilimumab. Patients who 
did not experience progressive disease after the induction 
period or toxicity requiring discontinuation of therapy were 
treated every 12 weeks in a maintenance setting and were con-
tinued on therapy until disease progression or unmanageable 
toxicity occurred (9%–20% of patients).
Phase iii trial shows improvement  
in overall survival in metastatic melanoma
The largest Phase III study completed to date with ipilimumab 
enrolled 676 patients with previously treated metastatic 
melanoma and HLA-A*0201-positive class I major histo-
compatibility complex proteins. The reason for HLA status 
prerequisite was due to the presence of glycoprotein 100 
(gp100) vaccine arms. Gp100 is one of the most common of the 
melanosomal proteins and is highly immunogenic. Its   ability 
to stimulate tumor-reactive T-cells has been   well-described 
and it was hypothesized that the addition of gp100   peptide 
vaccine to ipilimumab may enhance T-cell regulation and thus 
response rate compared with ipilimumab alone.30,31 The gp100 
epitope is presented to the immune   system in the context of 
HLA-A*0201 restricted peptides. As a result, patients were 
randomized in a 3:1:1 fashion to receive either ipilimumab 
3 mg/kg plus gp100 peptide   vaccine (n = 403), ipilimumab 
3 mg/kg alone (n = 137), or gp100 vaccine alone (n = 136). A 
retrospective analysis of previously published ipilimumab trials 
in metastatic melanoma noted similar median overall   survival 
rates regardless of HLA status.32 Treatment was administered 
every 3 weeks for four doses in an induction   setting. The pri-
mary endpoint of this study was initially designed to evaluate 
best overall response rate. After emergence of the Phase II data, 
and in coordination with another Phase III study, the primary 
endpoint was amended to overall survival (OS). For patients 
in the ipilimumab arms (alone or with gp100), median OS 
was 10.1 and 10.0 months, respectively, which was statisti-
cally significant compared to median OS of 6.4 months in 
the gp100 vaccine arm. This study allowed for re-induction 
ipilimumab in the originally assigned treatment regimen in 
patients who completed four doses of induction therapy and 
experienced stable disease or better at week 12 with subse-
quent disease progression. Thirty-one patients were treated 
with re-induction ipilimumab (23 with ipilimumab plus gp100 
vaccine; eight with ipilimumab alone); 21 patients (67.7%) 
achieved a response or stable disease with re-induction. On 
March 25, 2011, on the basis of this Phase III study, the US 
Food and Drug Administration (FDA) approved ipilimumab 
at a dose of 3 mg/kg for four induction doses to treat patients 
with metastatic melanoma. Due to previously published work, 
which noted no difference in overall survival or response 
rate based on HLA status, results of the Phase III trial can be 
extrapolated to ipilimumab-treated HLA-A*0201-negative 
patients.32 Another large, international, multi-center Phase III 
trial (NCT00324155) recently closed to enrollment and sought 
to compare OS, progression-free survival, and best overall 
response rate in dacarbazine plus ipilimumab 10 mg/kg vs 
dacarbazine plus placebo. Eligible patients (n = 502) were 
treated in the front-line metastatic setting with ipilimumab 
plus dacarbazine or placebo plus dacarbazine every 3 weeks 
for four doses followed by maintenance therapy. Although the 
overall response rate was not notably different between the two 
groups, the cohort receiving ipilimumab plus dacarbazine had 
a statistically significant improvement in the primary endpoint 
of OS compared to placebo plus dacarbazine (11.2 months 
vs 9.1 months).33
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Immune-related response criteria
Patterns of response to immunotherapy such as ipilimumab 
have historically varied from traditional responses seen 
with classical cytotoxic therapies. Stabilization of disease 
or slow regressions of tumors are expected responses; in 
addition, responses to ipilimumab have been demonstrated 
after initial tumor flare or tumor inflammation resulting 
in progressive disease. Likewise, the development of new 
lesions, while traditionally considered criteria for termination 
of other   treatments, does not always preclude a decrease in 
overall tumor burden in patients treated with ipilimumab. 
As such, traditional response criteria (WHO or RECIST) 
may underestimate the late responses seen with ipilimumab 
and deem treatment a clinical failure. The immunotherapy 
community, led by the Cancer Immunotherapy Consortium, 
previously the Cancer Vaccine Consortium, thereby led a 
process to review responses to immune-based treatments and 
establish new criteria which account for delayed response to 
therapy. This innovative set of criteria is known as immune-
related response criteria (irRC) and is a derivation of WHO 
criteria (Table 1).34 Approximately 8%–10% of patients evalu-
ated in the early Phase II ipilimumab trials had their responses 
changed from progressive disease to immune-related partial 
response using irRC.28,29 The Phase III studies of ipilimumab 




Ipilimumab induces autoimmune-like adverse events in treated 
patients. Across early studies, the most commonly encoun-
tered immune-mediate effects were dermatitis,   hepatitis, 
enterocolitis, hypophysitis, and uveitis.24,25 These effects are 
termed immune-related adverse events (irAEs). They appear 
most often during the induction phase of ipilimumab and were 
dose-related in early dose-escalation studies.26 Up to 80% of 
patients on clinical studies of ipilimumab reported irAEs, 
and 10%–17% of these are grade 3 or higher. The median 
time to resolution of immune-related adverse events was 
evaluated in one study and determined to be 6.3 weeks. In 
the Phase III trial of ipilimumab and gp100, there were 14 
deaths overall; eight in the ipilimumab plus gp100 arm, four 
in the ipilimumab alone arm, and two in the gp100 alone arm. 
Seven of these 14 were considered to be immune-related and 
the deaths which have been attributed to ipilimumab involved 
the gastrointestinal tract (bowel   perforation, enterocolitis, liver 
failure) and the nervous system (Guillain Barré syndrome).
The FDA was tasked with balancing safety and adverse events 
of ipilimumab and created a Risk Evaluation and Mitigation 
Strategy (REMS) program for ipilimumab upon approval. 
This program educates prescribing healthcare professionals 
about the risk of potentially severe irAEs that can occur while 
using ipilimumab.
Correlation between immune-related  
adverse events and response
Several studies have explored the theory that occurrence of 
irAE correlates with disease response. The earliest findings 
noted that patients with autoimmune toxicity were more 
likely to have tumor regression than patients who did not 
exhibit autoimmune toxicity (P = 0.008).23 In the Phase I/II 
study by Weber et al, all four objective responders also had 
an irAE.24 Additionally, 13 of 14 (93%) patients in this study 
who experienced stable disease had an irAE. Although the 
rate of irAE of any grade was 76%, there was no significant 
correlation between irAEs and response in this study. On 
further analysis, there was a significant correlation between 
grade 3 or 4 irAE and response in patients receiving ipili-
mumab at 10 mg/kg (P = 0.03). Another study found that 
patients with objective responses were noted to have more 
severe irAEs, and this finding was significant (P = 0.0004).35 
Although many patients with grade 0–2 irAEs experience 
clinical benefit either via disease stabilization or tumor 
regression, the disease control rate is higher in patients with 
grade 3–4 irAEs.29 It should be noted that the correlation 
between severe irAEs and response is most notable when 
ipilimumab is administered at 10 mg/kg and this correlation 
was not described in the Phase III trial which administered 
ipilimumab at 3 mg/kg.
Side effect management
Bristol-Myers Squibb has developed guidelines to assist health 
care professionals in the management of   immune-  mediated 
Table 1 Immune-related response criteria
Complete  
response
Disappearance of all lesions in two consecutive  
observations at least 4 weeks apart
Partial  
response
$50% decrease in tumor burden compared with  
baseline in two observations at least 4 weeks apart
Stable  
disease
,50% decrease in tumor burden compared with  




$25% increase in tumor burden compared with  




Do not automatically define progression; incorporated   
into tumor burden
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adverse reactions based upon affected body region.36 
  Gastrointestinal toxicity is frequently cited as an irAE 
that requires management and manifests as diarrhea or 
  enterocolitis. If symptoms are considered moderate, 4–6 stools 
per day over baseline or associated with abdominal pain, blood 
or mucus in the stool, ipilimumab should be withheld and 
antidiarrheal medications utilized until symptoms regress 
to at least a grade 1. If severe or life-threatening symptoms 
are present, $7 stools per day over baseline or associated 
with fever, ileus, or suspected bowel perforation, ipilimumab 
should be permanently discontinued and corticosteroids ini-
tiated at 1–2 mg/kg/day prednisone or methylprednisolone 
tapered slowly over 1 month. Concurrently, consideration 
of endoscopy is recommended, when appropriate. Systemic 
steroids should also be considered for the patient experienc-
ing moderate gastrointestinal effects whose symptoms do not 
respond after 1 week of supportive care.
For  patients  with  immune-mediated  dermatitis, 
  nonlocalized rash or diffuse rash #50% of skin surface can 
be managed by withholding ipilimumab and dispensation of 
topical or systemic corticosteroids. For severe dermatological 
effects such as Stevens–Johnson syndrome, toxic epidermal 
necrolysis, necrotic, bullous, or hemorrhagic desquamation, 
or full-thickness ulceration, ipilimumab should be perma-
nently discontinued and systemic corticosteroids adminis-
tered at 1–2 mg/kg/day of prednisone equivalent.
Management of other irAEs such as endocrinopathies 
driven by hypophysitis, neuropathies, respiratory and ocular 
manifestations, and hepatitis are also outlined in supplemental 
information provided by Bristol-Myers Squibb. In general, 
moderate irAEs can often be managed by withholding ipili-
mumab with or without supportive care while severe or life-
threatening irAEs often warrant permanent discontinuation 
of ipilimumab along with concurrent immunosuppressive 
therapy, most often in the form of systemic corticosteroids.
Conclusion
Melanoma is an immunogenic cancer, however, the immune 
system lacks the inherent capacity to eradicate melanoma 
tumors in most cases. Methods to enhance the ability of the 
immune system to attack melanoma have traditionally had 
marginal success, and served to remind us of the immense 
complexity of the balance between activating and inhibiting 
regulators of the immune system. Thus, it is noteworthy that the 
first randomized study to demonstrate a clear overall survival 
benefit in metastatic melanoma uses an immune-modulating 
agent. The effect of ipilimumab on metastatic melanoma is very 
encouraging and presents many intriguing further questions.
The use of ipilimumab has reinforced the need for oncolo-
gists to evaluate “tumor response” in a different manner than 
that used when using chemotherapeutic agents. Clinical 
responses can take months to appear given the need for an 
immune response to self-antigen to develop. Thus criteria, as 
presented in this review, are now being proposed to account 
for the difference seen when using immunologically-based 
therapies. The nature of response criteria will certainly have 
to be reviewed as new immune-based agents and combination 
therapies are developed.
Apart from the increase in median survival   (approximately 
4 months) seen with the use of ipilimumab, is the very encour-
aging durable complete responses (.5 years) that have been 
observed in some of the earliest melanoma patients to be 
treated with ipilimumab. It is clear that immunotherapies 
(eg, high dose IL-2, adoptive T-cell transfer, anti-PD-1, and 
anti-CTLA-4) have the capacity to induce a durable complete 
response in a small subset of patients. It is unclear if patients 
who have a durable response to one immunotherapy would 
be more likely to have the same response to another immu-
notherapy, or if different immune-modulating agents can 
have a beneficial effect in different populations of patients. 
The development of markers that predict which patients will 
respond to treatment and which will not, will also serve to 
optimize the use of these immune-modulating agents while 
limiting unnecessary toxicity.
The identification of activating gene mutations (eg, BRAF, 
NRAS, KIT, GNAQ, GNA11) in different subtypes of melanoma 
has created the opportunity to identify and inhibit activated 
growth and survival signaling pathways within melanoma 
tumor cells.37,38 It will be intriguing to see if the combination 
of immunotherapies with agents that target particular signaling 
pathways will enhance clinical response and overall survival, 
and most importantly long-term survival. Results from recent 
clinical trials have shown the efficacy of using small molecule 
inhibitors to target particular signaling pathway molecules. 
Vemurafenib, a BRAF mutant specific inhibitor recently 
gained FDA approval for use in advanced melanoma harbor-
ing the V600 mutation.39 Multiple reports have demonstrated 
clinical responses using a variety of tyrosine kinase inhibitors 
(imatinib, dasatinib, sunitinib) in KIT mutant melanoma.40–43 
Likewise, early reports suggest that small molecule MEK 
inhibitors that are currently being evaluated in clinical trials 
may have efficacy in different subtypes of melanoma.44
The recent FDA-approval of ipilimumab for unresectable 
or metastatic melanoma is a major advance in the treatment of 
melanoma, and will undoubtedly serve as the foundation of 
future treatment regimens.
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